In a groundbreaking collaboration between experts in Europe and the US, a pioneering clinical trial demonstrated that the treatment of stem cells may protect the brains of patients with multiple sclerosis (MS) from further damage.
The first-ever human trials revealed that patients injected with neural stem cells experienced no increase in disability or worsening of symptoms. In the year-long clinical trial, patients with advanced disability levels showed no increase in disability or symptoms, demonstrating the safety and potential efficacy of the treatment.
Despite acknowledged limitations, the findings are a significant step forward, paving the way for the next stage of clinical trials to develop cell therapy for treating multiple sclerosis.